Cancer Drug Development – Solasia Pharma
- Company Name: Solasia Pharma K.K.
- State/Prefecture: Tokyo Prefecture
- City/Town/Village: Minato-ku
- Street: 3F, Shiodome Building, 1-2-20, Kaigan
- Country: Japan
- Zip/Postal Code: 105-0022
- Phone: +81 3 6721 8332
- Website: http://solasia.co.jp/en/
- Contact: http://solasia.co.jp/en/contact/
- Listed: 11/12/2017 12:00 am
- Expires: This ad has expired
Solasia established in 2006, is a specialty pharmaceutical company based in Japan and Asia, with a mission of “Better Medicine for a Brighter Tomorrow”. In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient’s healthy living and to provide treatment options for the healthcare providers.
Solasia has been developing a wide range of products varying from pharmaceuticals for cancer therapy to supportive care for adverse event of drugs. Solasia has three product pipelines with our aspiration to deliver better medicines to the patients as soon as possible, one product of which pipelines was approved and one product is being examined for approval.
Ad Reference ID: 9465a06a2f82886e
Alcami got agreement with Solasia Pharma for Clinical Supply Solasia’s API Darinaparsin
Date: Nov 9, 2017
DURHAM, N.C., Nov. 9, 2017 – Alcami, a leading provider of custom end-to-end development and manufacturing services for the pharmaceutical and biotechnology industries, today announces it has finalized manufacturing and quality agreements with Solasia Pharma, K.K. (TSE: 4597) for the clinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a novel mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers.
Continue reading »